Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, Brock K, De Lavallade H, Craddock C, Clark RE, Smith ML, Fletcher R, Bishop R, Milojkovic D, Yap C. Copland M, et al. Among authors: clark re. Lancet Haematol. 2022 Feb;9(2):e121-e132. doi: 10.1016/S2352-3026(21)00370-7. Epub 2021 Dec 11. Lancet Haematol. 2022. PMID: 34906334 Clinical Trial.
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M. Clark RE, et al. Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26. Lancet Haematol. 2017. PMID: 28566209 Free article. Clinical Trial.
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M. Clark RE, et al. Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12. Lancet Haematol. 2019. PMID: 31201085 Free article. Clinical Trial.
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Claudiani S, Janssen JJWM, Byrne J, Smith G, Blijlevens N, Raghavan M, Smith M, Clark RE, Mclain-Smith S, Carter AM, Milojkovic D, Apperley JF. Claudiani S, et al. Among authors: clark re. Eur J Haematol. 2022 Jul;109(1):90-99. doi: 10.1111/ejh.13775. Epub 2022 May 17. Eur J Haematol. 2022. PMID: 35403752 Free PMC article.
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.
Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A; United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. Drummond MW, et al. Among authors: clark re. Br J Haematol. 2003 Nov;123(3):479-83. doi: 10.1046/j.1365-2141.2003.04599.x. Br J Haematol. 2003. PMID: 14617010 Free article.
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Ibrahim AR, et al. Among authors: clark re. Haematologica. 2011 Dec;96(12):1779-82. doi: 10.3324/haematol.2011.049759. Epub 2011 Aug 22. Haematologica. 2011. PMID: 21859733 Free PMC article. Clinical Trial.
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM, O'Brien S. Gallipoli P, et al. Among authors: clark re. Br J Haematol. 2022 Mar;196(6):e55-e57. doi: 10.1111/bjh.17961. Epub 2022 Jan 6. Br J Haematol. 2022. PMID: 34993961 Free PMC article. No abstract available.
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M. Kinstrie R, et al. Among authors: clark re. Leukemia. 2020 Jun;34(6):1613-1625. doi: 10.1038/s41375-019-0684-5. Epub 2020 Jan 2. Leukemia. 2020. PMID: 31896780 Free PMC article.
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Milojkovic D, Cross NCP, Ali S, Byrne J, Campbell G, Dignan FL, Drummond M, Huntly B, Marshall S, McMullin MF, Neelakantan P, Raghavan M, Sivakumaran M, Tighe J, Wandroo F, Willis F, Glen F, Fildes L, Collington SJ, Ryan J, Clark RE, Mead AJ. Milojkovic D, et al. Among authors: clark re. Br J Haematol. 2021 Jan;192(1):62-74. doi: 10.1111/bjh.16733. Epub 2020 May 24. Br J Haematol. 2021. PMID: 32449159 Free article.
738 results